Today’s Mains-Relevant Topics
- Space Oncology: The New Frontier in Cancer Treatment — GS PAPER III — Science & Technology | GS PAPER II — Health Governance
- UAPA and the Changing Legal Dimensions of Bail — GS PAPER II — Polity, Governance & Judiciary
| Struggling to Structure 250-Word Answers Under Time Pressure? Explore Mentorship Resources for Answer Writing → |
| Space Oncology: The New Frontier in Cancer Treatment GS PAPER III — Science & Technology | GS PAPER II — Health Governance |
| Why in News? India’s cancer burden keeps climbing, with an estimated 1.87 lakh new cases projected for 2026. Against this backdrop, a field called ‘Space Oncology’ is drawing serious scientific attention. It uses two conditions unique to space — microgravity and cosmic radiation — to study how cancer cells behave and to manufacture better cancer drugs. |
What Exactly Is Space Oncology
Space oncology sits at the intersection of medical science and space biology. It relies on two extra-terrestrial conditions that simply cannot be replicated on Earth.
Microgravity, the near-absence of gravitational pull in orbit, fundamentally changes how cells grow and interact. Cosmic radiation, encountered once a spacecraft leaves Earth’s protective atmosphere, offers a natural setting to observe DNA mutation and how cancer cells respond to stress.
Why Earth-Grown Cancer Models Fall Short
On Earth, gravity forces laboratory-grown cells into flat, two-dimensional layers that poorly mimic how tumours actually behave inside the human body. Space removes that constraint.
Four Advantages the Space Environment Offers
In microgravity, cells spontaneously assemble into three-dimensional spherical clusters — called 3D spheroids — without needing any artificial scaffolding, giving researchers a far more realistic tumour model.
The cytoskeleton and cell-to-cell signalling of cancer cells also change in orbit. Breast cancer cells, for instance, turn less aggressive in space, making their vulnerabilities easier to identify, while gastric cancer cells become more sensitive to treatment.
Because there is no sedimentation — the settling of particles under gravity — protein crystals and nanoparticles grown in space come out purer, more uniform, and less viscous, which improves drug effectiveness.
Better 3D tumour models grown in orbit also reduce how much researchers need to rely on animal testing during early drug development.
Why This Matters for India
Cancer is not merely a health emergency in India — it is a financial one. Families collectively spend roughly ₹3,400 crore every year on direct and indirect cancer-related expenses.
India is well placed to respond. Its space economy, currently valued near $13 billion, sits atop a space programme that ranks third globally in technological capability. With the Gaganyaan human spaceflight mission advancing and a growing base of private space startups, India has a realistic shot at sending low-cost pharmaceutical payloads into orbit — positioning itself as a hub for ‘in-orbit drug manufacturing’.
Early Evidence From Real Case Studies
No patient is being treated in space today, but drugs developed there are already reaching patients on Earth.
NASA grew crystals of Pembrolizumab, a well-known cancer immunotherapy drug, aboard the International Space Station. These crystals were so precise and stable that the US FDA approved a subcutaneous version in 2025 — letting patients self-inject at home instead of undergoing IV infusion.
Rebexinib became the first anti-cancer drug tested in space to receive ‘Investigational New Drug’ status from the FDA, clearing it for clinical trials.
On the regulatory side, the United Kingdom in 2026 scrapped ‘dual regulation’ requirements for space-based pharmacology, letting companies deploy compact in-orbit manufacturing units more freely.
The Roadblocks That Remain
Sending payloads to Low Earth Orbit remains expensive, even with cheaper reusable rockets. Bringing live cell cultures safely back to Earth without damaging them is a delicate logistical challenge.
Cancer cells also behave unpredictably in space — breast cancer cells grow less lethal, while gastrointestinal and colorectal cancers turn more aggressive. And there is still no unified global legal framework governing patents, quality control, or clinical trials for medicines manufactured off-planet.
Traditional vs Modern Cancer Technologies
| Technology | Working Mechanism | Main Benefits | Limitations/Challenges |
| Traditional Chemo/Radiation | Kills cancer cells on Earth using chemical drugs or X-rays | Widely available and well established | Damages healthy cells (side-effects); drug resistance |
| Immunotherapy (Earth-based) | Activates the body’s own immune system to fight cancer | Targeted therapy | Very expensive; long IV infusions due to high fluid viscosity |
| Space Oncology | 3D tumour modelling and pure nanoparticle crystallisation in microgravity | Highly stable drugs, painless home-injection delivery, less animal testing | High launch costs, space logistics, regulatory barriers |
The Way Forward
- A Public-Private Partnership between ISRO, the Department of Biotechnology, and private pharma companies to jointly develop ‘bio-payloads’ for orbital research.
- Deploying unmanned nano-satellites (CubeSats) with robotic systems that can autonomously manufacture drug crystals without human presence in orbit.
- India taking a lead role with the WHO and the UN Office for Outer Space Affairs to draft global standards for medicines manufactured in space.
With the global microgravity pharma market approaching $9.8 billion, space oncology is emerging as a genuine leap toward more effective cancer care. Set against WHO’s warnings in its Global Cancer Burden Report, this innovation offers a fresh route to SDG 3 (Good Health and Well-being) — pushing cancer treatment beyond the boundaries Earth’s gravity has always imposed.
| UPSC Note — Mains Answer-Writing Angle This topic falls under GS PAPER III — Science & Technology | GS PAPER II — Health Governance. Use it to add current, data-backed examples to otherwise theoretical GS answers. Examiners reward specific numbers, case laws and scheme names over generic statements — anchor your answer accordingly. |
| Points to Include in Your Answer Define space oncology through its two pillars — microgravity and cosmic radiation.Use the 3D spheroid and protein-crystal advantages as your technical core.Cite the Pembrolizumab and Rebexinib case studies as concrete evidence of real-world impact.Bring in India’s angle: ₹3,400 crore annual cancer cost burden vs Gaganyaan/private space capability.Close with the PPP + CubeSat + global regulatory framework way-forward, linked to SDG 3. |
| Mains Practice Question ‘Space Oncology and microgravity-based drug manufacturing are setting new paradigms in the field of biomedicine.’ Discuss how this technology can be helpful in reducing the healthcare and economic burden in a developing country like India. (250 words, 15 marks) |
| Want Personal Feedback on Every Answer You Write? Join the UPSC Mentorship Program → |
| UAPA and the Changing Legal Dimensions of Bail GS PAPER II — Polity, Governance & Judiciary |
| Why in News? Long-pending bail pleas of student activists in the 2020 Delhi riots case, along with contradictory judicial rulings, have reopened a sharp debate on the right to a fair trial and indefinite incarceration without trial in India. At its core, the debate weighs personal liberty under Article 21 against the State’s security concerns under a stringent law — the Unlawful Activities (Prevention) Act, or UAPA. |
When ‘The Process Becomes the Punishment’
Many accused under UAPA have spent five to six years or more in jail without their trial even beginning. Courts, meanwhile, have been strikingly inconsistent: Kashmiri human rights activist Khurram Parvez secured bail after four years in detention, while other accused facing similarly long periods of custody have had bail denied purely on the ground of the offence’s gravity.
How Section 43D(5) Reverses the Normal Rule on Bail
General criminal law follows a simple principle: bail is the rule, jail is the exception. Section 43D(5) of UAPA flips this on its head — if a court finds, based on the case diary or police report, that the accusations appear prima facie true, it cannot grant bail at all, regardless of how long the trial is taking.
What the Courts Have Said
In K.A. Najib vs Union of India (2021), the Supreme Court held that even the strict statutory bar under Section 43D(5) cannot override the constitutional right to a speedy trial guaranteed by Article 21. Where trial delays become excessive, constitutional courts retain the power to grant bail.
In Shaheen Abdullah vs Union of India, the Court reiterated that the State cannot detain any citizen indefinitely without trial, since that would violate the rule of law. Altesham Ahmad vs State made a similar point — prolonged under-trial detention runs contrary to basic principles of justice.
Deeper Structural Problems With the Law
At the bail stage, ‘gravity of the offence’ is still just an allegation made by the State, not a proven fact. When courts deny bail for years based on that allegation alone, without weighing the actual evidence, civil rights take a real hit.
Critics and international human rights bodies argue that such stringent laws often blur the line between genuine terrorism and political dissent. Compounding this, conviction rates in UAPA cases remain low, yet the long judicial process means the accused loses the most productive years of their life in custody before any acquittal.
Bail Provisions: General Criminal Law vs UAPA
| Feature | General Law (CrPC/BNSS) | UAPA (1967) |
| Basic principle | Bail is a rule, jail is an exception | Jail becomes primary; bail is extremely difficult |
| Discretion of court | Bench decides based on facts and likelihood of witness-tampering | Under Section 43D(5), if charges appear prima facie true, the court’s hands are tied |
| Constitutional protection | Full respect for speedy trial and liberty under Article 21 | Stringent statutory restrictions on liberty in the name of national security |
UAPA and NCRB Data Trends at a Glance
| Indicator | NCRB Key Figures | Analytical Point |
| Rising cases | 2020: 796 | 2021: 814 | 2022: 1,005 (~23% rise) | Cases have climbed steadily since the 2019 amendment allowing individuals to be designated as terrorists |
| Geographical concentration | Over 60% of cases concentrated in a few states — J&K (371), Manipur (167), Assam (133), Uttar Pradesh (101) in 2022 | Law is used predominantly in internally security-sensitive and border regions |
| Delay in investigation | Chargesheet pendency at 80–85%; UAPA allows 180 days for investigation vs 60–90 days under general law | Extended investigation window stretches out pre-trial detention |
| Judicial pendency | 94–95% pendency rate for trials in special courts | Fewer than 5% of cases conclude trial each year — the process itself becomes the punishment |
| Conviction rate | 21.1–29.2% of completed trials end in conviction; under 3% when measured against total arrests (NCRB/PUCL data) | Many are arrested in a single conspiracy case, but a lack of evidence means very few are ultimately convicted |
The Way Forward
- A larger Supreme Court bench, constituted by the Chief Justice of India, laying down clear, consistent guidelines to end contradictory rulings across benches and High Courts.
- Time-bound trials — requiring the State to present preliminary evidence within a fixed period, such as six months to a year, failing which bail becomes mandatory.
- Greater judicial accountability, with judges retaining firm control over trial timelines so that the process itself never substitutes for punishment.
In a democracy governed by the rule of law, national security and personal liberty must carry equal weight. Holding a citizen in jail for years without conviction, in the name of security alone, sits uneasily with constitutional morality. Courts must ensure stringent laws like UAPA are never allowed to blur into tools for suppressing dissent — keeping faith with both Article 21 and the spirit of Satyamev Jayate.
| UPSC Note — Mains Answer-Writing Angle This topic falls under GS PAPER II — Polity, Governance & Judiciary. Use it to add current, data-backed examples to otherwise theoretical GS answers. Examiners reward specific numbers, case laws and scheme names over generic statements — anchor your answer accordingly. |
| Points to Include in Your Answer Frame the tension clearly: Article 21’s right to a speedy trial versus Section 43D(5)’s reversal of the bail principle.Cite K.A. Najib (2021) as the anchor judgment, and add Shaheen Abdullah and Altesham Ahmad for depth.Use NCRB data (rising cases, <3% conviction on total arrests, 94–95% trial pendency) to evidence the ‘process as punishment’ argument.Acknowledge the State’s security rationale before critiquing its implementation — this shows balance.End with concrete reform: larger-bench guidelines + time-bound trial mandate. |
| Mains Practice Question ‘The stringent provisions of bail under Section 43D(5) of UAPA often clash with the right to a speedy trial guaranteed under Article 21.’ Discuss with reference to major judicial decisions how the judiciary can strike a balance between the two. (250 words, 15 marks) |
| Also Read Role of Personal Mentorship in GS Preparation Daily Answer Writing: Mock Tests That Help UPSC Aspirants Bounce Back |
| External References Union Public Service Commission — upsc.gov.in Indian Space Research Organisation — isro.gov.in National Crime Records Bureau — ncrb.gov.in |
| Ready to Get a Personal Mentor for UPSC 2027? Apply Now → |
